User login
The addition of candesartan (Atacand) to an angiotensin-converting enzyme (ACE) inhibitor and other treatment reduces cardiovascular death and hospital admissions of patients with congestive heart failure (CHF). As in studies conducted with valsartan (Diovan), candesartan added to an ACE inhibitor does not decrease overall mortality. Clinicians should add candesartan to the medical regimen in nonallergic CHF patients with an ejection fraction of 40% or lower who are already on an optimal dose of an ACE inhibitor.
The addition of candesartan (Atacand) to an angiotensin-converting enzyme (ACE) inhibitor and other treatment reduces cardiovascular death and hospital admissions of patients with congestive heart failure (CHF). As in studies conducted with valsartan (Diovan), candesartan added to an ACE inhibitor does not decrease overall mortality. Clinicians should add candesartan to the medical regimen in nonallergic CHF patients with an ejection fraction of 40% or lower who are already on an optimal dose of an ACE inhibitor.
The addition of candesartan (Atacand) to an angiotensin-converting enzyme (ACE) inhibitor and other treatment reduces cardiovascular death and hospital admissions of patients with congestive heart failure (CHF). As in studies conducted with valsartan (Diovan), candesartan added to an ACE inhibitor does not decrease overall mortality. Clinicians should add candesartan to the medical regimen in nonallergic CHF patients with an ejection fraction of 40% or lower who are already on an optimal dose of an ACE inhibitor.